Parenteral aminoacid strategies for nutritional optimization in low birth weight infants

Cynthia Blanco, Julie C. Hisey

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Parenteral amino acid (AA) supplementation is vital for appropriate nutrition in preterm infants. Amino acids and proteins are essential components of growth, development, and regulation of metabolism. Growth restriction during this vulnerable time has been negatively associated with short-/longterm outcomes. In order to improve postnatal growth to that which parallels a healthy, growing fetus, it is important to mimic AA accretion by the fetus. Early loss of protein stores can be prevented or minimized by provision of as little as 1-1.5 g/kg/day of parenteral AA. The minimum AA requirement necessary to approximate intrauterine rates of protein accretion is Â3 g/kg/day, but the placenta serves as a metabolic organ in utero; premature infants may not have mature metabolic pathways and therefore, may not tolerate the same protein load ex-utero. Although BUN may correlate with AA plasma levels, it cannot effectively be utilized to assess protein accretions, but a level >60 mg/dL may suggest immature metabolic pathways in the absence of renal disease. With the current data available, Parenteral AA supplementation should be started shortly after birth at a minimum dose of 1-1.5 g/kg/day to prevent catabolism in all VLBW infants. A maximum of 3.5 g/kg/day is recommended until enteral nutrition is established for VLBW infants. Higher doses of protein supplementation have not shown additional benefits and may cause deleterious effects in overall growth and neurodevelopment. Additional glutamine and/or higher L-cysteine or arginine supplementation does not provide additional benefits. Larger randomized controlled trials that examine long-term outcomes are needed to develop a safe and maximally beneficial AA administration strategy

Original languageEnglish (US)
Title of host publicationDiet and Nutrition in Critical Care
PublisherSpringer New York
Pages1957-1969
Number of pages13
ISBN (Print)9781461478362, 9781461478379
DOIs
StatePublished - Jan 1 2015

Fingerprint

Low Birth Weight Infant
Amino Acids
Proteins
Metabolic Networks and Pathways
Premature Infants
Nutrition
Fetus
Growth
Essential Amino Acids
Blood Urea Nitrogen
Enteral Nutrition
Glutamine
Growth and Development
Placenta
Cysteine
Arginine
Metabolism
Randomized Controlled Trials
Parturition
Kidney

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Blanco, C., & Hisey, J. C. (2015). Parenteral aminoacid strategies for nutritional optimization in low birth weight infants. In Diet and Nutrition in Critical Care (pp. 1957-1969). Springer New York. https://doi.org/10.1007/978-1-4614-7836-2_150

Parenteral aminoacid strategies for nutritional optimization in low birth weight infants. / Blanco, Cynthia; Hisey, Julie C.

Diet and Nutrition in Critical Care. Springer New York, 2015. p. 1957-1969.

Research output: Chapter in Book/Report/Conference proceedingChapter

Blanco, C & Hisey, JC 2015, Parenteral aminoacid strategies for nutritional optimization in low birth weight infants. in Diet and Nutrition in Critical Care. Springer New York, pp. 1957-1969. https://doi.org/10.1007/978-1-4614-7836-2_150
Blanco, Cynthia ; Hisey, Julie C. / Parenteral aminoacid strategies for nutritional optimization in low birth weight infants. Diet and Nutrition in Critical Care. Springer New York, 2015. pp. 1957-1969
@inbook{e1720d95d52d4280b3197930456c7272,
title = "Parenteral aminoacid strategies for nutritional optimization in low birth weight infants",
abstract = "Parenteral amino acid (AA) supplementation is vital for appropriate nutrition in preterm infants. Amino acids and proteins are essential components of growth, development, and regulation of metabolism. Growth restriction during this vulnerable time has been negatively associated with short-/longterm outcomes. In order to improve postnatal growth to that which parallels a healthy, growing fetus, it is important to mimic AA accretion by the fetus. Early loss of protein stores can be prevented or minimized by provision of as little as 1-1.5 g/kg/day of parenteral AA. The minimum AA requirement necessary to approximate intrauterine rates of protein accretion is {\^A}3 g/kg/day, but the placenta serves as a metabolic organ in utero; premature infants may not have mature metabolic pathways and therefore, may not tolerate the same protein load ex-utero. Although BUN may correlate with AA plasma levels, it cannot effectively be utilized to assess protein accretions, but a level >60 mg/dL may suggest immature metabolic pathways in the absence of renal disease. With the current data available, Parenteral AA supplementation should be started shortly after birth at a minimum dose of 1-1.5 g/kg/day to prevent catabolism in all VLBW infants. A maximum of 3.5 g/kg/day is recommended until enteral nutrition is established for VLBW infants. Higher doses of protein supplementation have not shown additional benefits and may cause deleterious effects in overall growth and neurodevelopment. Additional glutamine and/or higher L-cysteine or arginine supplementation does not provide additional benefits. Larger randomized controlled trials that examine long-term outcomes are needed to develop a safe and maximally beneficial AA administration strategy",
author = "Cynthia Blanco and Hisey, {Julie C.}",
year = "2015",
month = "1",
day = "1",
doi = "10.1007/978-1-4614-7836-2_150",
language = "English (US)",
isbn = "9781461478362",
pages = "1957--1969",
booktitle = "Diet and Nutrition in Critical Care",
publisher = "Springer New York",

}

TY - CHAP

T1 - Parenteral aminoacid strategies for nutritional optimization in low birth weight infants

AU - Blanco, Cynthia

AU - Hisey, Julie C.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Parenteral amino acid (AA) supplementation is vital for appropriate nutrition in preterm infants. Amino acids and proteins are essential components of growth, development, and regulation of metabolism. Growth restriction during this vulnerable time has been negatively associated with short-/longterm outcomes. In order to improve postnatal growth to that which parallels a healthy, growing fetus, it is important to mimic AA accretion by the fetus. Early loss of protein stores can be prevented or minimized by provision of as little as 1-1.5 g/kg/day of parenteral AA. The minimum AA requirement necessary to approximate intrauterine rates of protein accretion is Â3 g/kg/day, but the placenta serves as a metabolic organ in utero; premature infants may not have mature metabolic pathways and therefore, may not tolerate the same protein load ex-utero. Although BUN may correlate with AA plasma levels, it cannot effectively be utilized to assess protein accretions, but a level >60 mg/dL may suggest immature metabolic pathways in the absence of renal disease. With the current data available, Parenteral AA supplementation should be started shortly after birth at a minimum dose of 1-1.5 g/kg/day to prevent catabolism in all VLBW infants. A maximum of 3.5 g/kg/day is recommended until enteral nutrition is established for VLBW infants. Higher doses of protein supplementation have not shown additional benefits and may cause deleterious effects in overall growth and neurodevelopment. Additional glutamine and/or higher L-cysteine or arginine supplementation does not provide additional benefits. Larger randomized controlled trials that examine long-term outcomes are needed to develop a safe and maximally beneficial AA administration strategy

AB - Parenteral amino acid (AA) supplementation is vital for appropriate nutrition in preterm infants. Amino acids and proteins are essential components of growth, development, and regulation of metabolism. Growth restriction during this vulnerable time has been negatively associated with short-/longterm outcomes. In order to improve postnatal growth to that which parallels a healthy, growing fetus, it is important to mimic AA accretion by the fetus. Early loss of protein stores can be prevented or minimized by provision of as little as 1-1.5 g/kg/day of parenteral AA. The minimum AA requirement necessary to approximate intrauterine rates of protein accretion is Â3 g/kg/day, but the placenta serves as a metabolic organ in utero; premature infants may not have mature metabolic pathways and therefore, may not tolerate the same protein load ex-utero. Although BUN may correlate with AA plasma levels, it cannot effectively be utilized to assess protein accretions, but a level >60 mg/dL may suggest immature metabolic pathways in the absence of renal disease. With the current data available, Parenteral AA supplementation should be started shortly after birth at a minimum dose of 1-1.5 g/kg/day to prevent catabolism in all VLBW infants. A maximum of 3.5 g/kg/day is recommended until enteral nutrition is established for VLBW infants. Higher doses of protein supplementation have not shown additional benefits and may cause deleterious effects in overall growth and neurodevelopment. Additional glutamine and/or higher L-cysteine or arginine supplementation does not provide additional benefits. Larger randomized controlled trials that examine long-term outcomes are needed to develop a safe and maximally beneficial AA administration strategy

UR - http://www.scopus.com/inward/record.url?scp=84945156689&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84945156689&partnerID=8YFLogxK

U2 - 10.1007/978-1-4614-7836-2_150

DO - 10.1007/978-1-4614-7836-2_150

M3 - Chapter

AN - SCOPUS:84945156689

SN - 9781461478362

SN - 9781461478379

SP - 1957

EP - 1969

BT - Diet and Nutrition in Critical Care

PB - Springer New York

ER -